For years, the company has been regarded as OTC slop, but two major catalysts over the next 24 months could boost growth and potentially triple or quadruple FCF for an already cash-flowing business.
Because of these catalysts, looking at standard EV multiples or ROIC figures is essentially useless.
Read until the end and you’ll get 2 or 3 valuable insights that Claude simply can't grasp… drawn both from our deep understanding of FDA approval pathways (like we broke down for MODD) and direct conversations with stakeholders.
Hold onto your seat and let’s break this one down.
As we now do every week for transparency, here is our list of past Pick of the Week posts and their returns since publishing:
All picks (equally weighted): +21.06%
Our picks (executed): +29.83%
Note: We’ve been traveling since Thursday to visit companies, so this data was last updated on August 20th. Moving forward we will eliminate any picks we don’t hold past one year. You may notice CROX is our #2 PoW.
Pick of the Week. A curated series of high-conviction research on companies currently under our microscope. We screen for specific dislocations where the market has mispriced the balance sheet or earnings power.
None of the following should be construed as investment advice. Please consult a financial advisor before making any investment decision. You will find a full disclaimer at the end of this post.
💊 Elite Pharmaceuticals Inc. ($ELTP)
⭐ Overall Grade: 8.5 / 10
Elite Pharmaceuticals ($ELTP) has executed an internal model turnaround by transitioning from a partner-dependent R&D shop into a vertically integrated specialty generic manufacturer, capturing all of the downstream margins under its proprietary “Elite Labs” label.